Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$10.9MCash on Hand
12.8mo Cash Runway
Follow GRI by emailGet an email when GRI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GRI, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Shareholder vote Shareholders approved an amendment to the 2018 Equity Incentive Plan adding 546,529 shares and extending the evergreen provision to January 1, 2036, and elected W. Marc Hertz, Ph.D. and David Szekeres as Class III directors at the November 4, 2026 annual meeting, with 42.37% of eligible shares present. Form 8-K · SEC filing
Sep 28, 2026 ·
Shareholder vote GRI Bio will hold its 2026 annual meeting virtually on November 4, 2026, with a record date of September 22, 2026. Stockholders will vote on electing W. Marc Hertz, Ph.D. Form DEF 14A · SEC filing
Sep 8, 2026 ·
Clinical trial Posted an updated corporate presentation and issued a press release with new translational biomarker data from the Phase 2a study of GRI-0621 (oral tazarotene) in idiopathic pulmonary fibrosis. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2025 · Phase 2 · Results Expected · Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not GRI's own candidates): Tazarotene.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
GRI holds $10.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.6M/quarter from operations,
an estimated runway of 12.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:58 · Elevated
Cash runway 13 months +18
ATM program on file since Jan 2026 +15
Shelf registration (S-3, Jan 2026) +10
Going-concern doubt in the latest 10-Q +15Therefore, there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Jan 30, 2026 · Shelf registration, up to $250M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.